We, the undersigned Members of the European Parliament, want to convey our deep concerns regarding the safety and ineffectiveness of COVID-19 vaccines and we believe it is imperative that immediate and resolute actions should be taken.
We therefore request the direct suspension of the marketing authorizations of the following COVID-19 vaccines:
- Conditional Marketing Authorisation Pfizer (Comirnaty) dated 21 December 2020.1
- Conditional Marketing Authorisation Moderna (Spikevax) dated 6 January 2021.2
- Renewal of Marketing Authorisation Pfizer (Comirnaty-tozinameran) dated 31 August 2023.3
- Renewal Marketing Authorisation Moderna (Spikevax-elasomeran) dated 15 September 2023.4
In this letter, we aim to provide a comprehensive, though not exhaustive, rationale for our urgent plea.
Nevertheless, we request you, as a governing body that is legally obligated to take a careful consideration, to broaden your perspective beyond the issues and deficiencies we have cited. The discourse surrounding COVID-19 vaccines has been marked by a disconcerting upsurge in reported side effects, and, astonishingly, there have even been alarming reports of excess mortality. All of this has unfolded beneath a veil of unwarranted secrecy.
(...)
Your role as a medicines agency carries an inherent commitment to the principles of good administration and good medical practice. Failing to suspend the marketing authorizations in question would not only be incongruent with these principles but may also implicate human rights considerations, given the gravity of the issues at hand.
The stakes involved encompass not only the well-being of our citizens but also the allocation of taxpayers' funds.
Therefore, it is imperative that immediate action is taken to suspend the following marketing authorizations:
- Conditional Marketing Authorisation Pfizer (Comirnaty) dated 21 December 2020.;50
- Conditional Marketing Authorisation Moderna (Spikevax) dated 6 January 202151
- Renewal of Marketing Authorisation Pfizer (Comirnaty-tozinameran) dated 31 August 2023;52
- Renewal Marketing Authorisation Moderna (Spikevax-elasomeran) dated 15 September 2023.53
We kindly request an acknowledgment of receipt and anticipate a comprehensive response to this request at your earliest convenience.
Sincerely,
Marcel de Graaff (Member of the European Parliament)
Gilbert Collard (Member of the European Parliament)
Francesca Donato (Member of the European Parliament)
Joachim Kuhs (Member of the European Parliament)
Mislav Kolakušić (Member of the European Parliament)
Virginie Joron (Member of the European Parliament)
Ivan Vilibor Sinčić (Member of the European Parliament)
Bernhard Zimniok (Member of the European Parliament)
Invocando no solo principios de buena administración (art 41 CDFUE), sino también razones sanitarias, de adecuada utilización de fondos públicos y de protección de derechos fundamentales
— Guillermo Ruiz Zapatero (@ruiz_zapatero) October 26, 2023
No comments:
Post a Comment